top of page

Moderna CEO Stéphane Bancel walks us through Moderna and Merck's 3-year individual neoantigen therapy + Keytruda adjuvant melanoma data at #ASCO24 and Moderna's broader oncology pipeline

  • blonca9
  • Jun 3, 2024
  • 1 min read

At Moderna's analyst meeting at #ASCO24 in Chicago, Stéphane Bancel shows the Kaplan-Meier curve separation over time for the neoantigen platform in melanoma, and also discusses Moderna's intratumoral platform, and how mRNA can work with new modalities like bispecifics and cell therapies.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Genezen_Logo_RGB.png

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

bottom of page